JPRN-jRCT2032230318
Recruiting
Phase 1
A single-arm exploratory clinical trial to evaluate the safety and efficacy of subcutaneous embedding of the pluripotent stem cell accumulating device (BSM1) and patch treatment of diabetic foot ulcers using Biiosheets obtained from BSM1
Higashita Ryuji0 sites10 target enrollmentSeptember 4, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Diabetic foot ulcers unhealed with standard treatment or requiring extra-resection of proximal sites
- Sponsor
- Higashita Ryuji
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Age is over 18 years old
- •(2\) Type 1 or type 2 diabetic mellitus
- •(3\) Having an unhealed diabetic foot ulcer by standard wound treatment
- •(4\) Chronic limb threatening ischemia that meets W\-1 to 3, I\-0 to 2, fI\-0 to 2, and clinical stage 3 or 4 in WIfI classification
- •(5\) Patients correspond to one of the following
- •a. Foot and/or heal ulcer allow for over 4cm2 wound area after the debridement
- •b. Foot gangrene allow for the additional resection including the healthy proximal site
- •(6\) Survival of 12 months or more and followed\-up for 12 weeks after the treatment are possible.
- •(7\) Agreement for participating in the study and informed consent signed by the patient.
Exclusion Criteria
- •(1\) Patients who have difficulty in securing the implantation period of the clinical trial equipment required for Biotube formation.
- •(2\) Patients with general condition who are difficult to tolerate surgery due to severe malnutrition and complications.
- •(3\) Patients with poor skin condition who cannot secure more than one implantation site for the investigational device.
- •(4\) Patients undergoing invasive surgery except wound care (debridement) or revascularization within 30 days prior to enrollment
- •(5\) Patients who have a history of allergies to stainless steel or polyolefin resin
- •(6\) Poor control blood sugar level (Fasting blood sugar \> 200 mg/dl)
- •(7\) History and complications of malignant tumors (excludes those with no recurrence for more than 5 years after treatment or new onset).
- •(8\) Participating in other clinical trials within 3 months prior to enrollment.
- •(9\) History of experiences of this device or Biosheet
- •(10\) Patients who use immunosuppressants for autoimmune diseases and post\-implantation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Phyllantus niruri mother tincture in non alcoholic fatty liver diseaseHealth Condition 1: K77- Liver disorders in diseases classified elsewhereCTRI/2022/07/044256Dr Amit
Completed
Not Applicable
The prospective single-arm clinical trial to evaluate safety and efficacy of the training program for esophageal smooth muscle in patients with gastro-esopheal reflux disease.gastro-esophageal reflux diseaseJPRN-UMIN000047829ishijin Hospital20
Not yet recruiting
Phase 2
Effect of ayurvedic medicine in anxiety of working womeHealth Condition 1: F411- Generalized anxiety disorderCTRI/2020/10/028443Dr Samir S Holkar
Recruiting
Not Applicable
The MitraClip System ANZ Clinical Trial is a prospective single arm clinical trial for men and women with significant, chronic mitral regurgitation to gather real-world clinical and health-economic outcome data to support the long-term safety, efficacy and economic value of the MitraClip System for treating mitral regurgitatioMitral RegurgitationCardiovascular - Other cardiovascular diseasesACTRN12613000020785Evalve, Inc. A subsidiary of Abbott Vascular Inc.150
Active, not recruiting
Phase 3
A Japanese phase III multicenter, single-arm, open-label clinical trial to assess the efficacy and safety of the diagnosis/treatment of lymphedema by ICG fluorescent lymphangiography in patients with secondary lymphedemaJPRN-jRCT2031190064Akita Shinsuke50